Base de dados : MEDLINE
Pesquisa : C15.378.140.855.850 [Categoria DeCS]
Referências encontradas : 283 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 29 ir para página                         

  1 / 283 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675682
[Au] Autor:Kovanlikaya A; Tiwari P; Bussel JB
[Ad] Endereço:Division of Pediatric Radiology, Department of Radiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York.
[Ti] Título:Imaging and management of fetuses and neonates with alloimmune thrombocytopenia.
[So] Source:Pediatr Blood Cancer;64(12), 2017 Dec.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is the most common cause of severe neonatal thrombocytopenia and intracranial bleeding in term newborns. Intracranial hemorrhage (ICH) commonly results in death or severe, lasting neurologic disability. The timing of ICH is also important for management of the next affected pregnancy in cases of FNAIT. This manuscript reviews the advantages and disadvantages of the different radiologic methodologies to identify and characterize ICH. It discusses the limits of ultrasound and the advantages of magnetic resonance imaging allowing avoidance of the radiation associated with computed tomography (CT) scans.
[Mh] Termos MeSH primário: Doenças Fetais/diagnóstico por imagem
Hemorragias Intracranianas/diagnóstico por imagem
Trombocitopenia Neonatal Aloimune/diagnóstico por imagem
Trombocitopenia Neonatal Aloimune/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Imagem por Ressonância Magnética
Gravidez
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26690


  2 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28644735
[Au] Autor:Winkelhorst D; Oepkes D; Lopriore E
[Ad] Endereço:a Division of Fetal Therapy, Department of Obstetrics , Leiden University Medical Center , Leiden , The Netherlands.
[Ti] Título:Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.
[So] Source:Expert Rev Hematol;10(8):729-737, 2017 Aug.
[Is] ISSN:1747-4094
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare but potentially lethal disease, leading to severe bleeding complications in 1 in 11.000 newborns. It is the leading cause of thrombocytopenia in healthy term-born neonates. Areas covered: This review summarizes the antenatal as well as postnatal treatment, thus creating a complete overview of all possible management strategies for FNAIT. Expert commentary: The optimal antenatal therapy in order to prevent bleeding complications in pregnancies complicated by FNAIT is non-invasive treatment with weekly intravenous immunoglobulin (IVIG). Based on risk stratification, weekly doses of IVIG of 0.5 or 1.0g/kg should be administered started early in the second in high risk cases or at the end of the second trimester in low risk cases. The optimal postnatal treatment depends on the platelet count and the clinical condition of the newborn. Prompt administration of compatible platelet transfusion is the first treatment of choice in case of severe thrombocytopenia or active bleeding. In case matched platelets are not directly available, random platelets can also be administered initially to gain time until matched platelets are available. In case of persistent thrombocytopenia despite transfusions, IVIG 1.0-2.0g/kg can be administered.
[Mh] Termos MeSH primário: Doenças Fetais/diagnóstico
Doenças Fetais/terapia
Trombocitopenia Neonatal Aloimune/diagnóstico
Trombocitopenia Neonatal Aloimune/terapia
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Gerenciamento Clínico
Medicina Baseada em Evidências
Feminino
Seres Humanos
Imunoglobulinas Intravenosas
Recém-Nascido
Assistência Perinatal
Transfusão de Plaquetas
Gravidez
Medição de Risco
Trombocitopenia Neonatal Aloimune/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE
[do] DOI:10.1080/17474086.2017.1346471


  3 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28401538
[Au] Autor:Winkelhorst D; Loeff RM; van den Akker-Van Marle ME; de Haas M; Oepkes D
[Ad] Endereço:Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.
[Ti] Título:Women's attitude towards routine human platelet antigen-screening in pregnancy.
[So] Source:Acta Obstet Gynecol Scand;96(8):991-997, 2017 Aug.
[Is] ISSN:1600-0412
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Fetal and neonatal alloimmune thrombocytopenia is a potentially life-threatening disease with excellent preventative treatment available for subsequent pregnancies. To prevent index cases, the effectiveness of a population-based screening program has been suggested repeatedly. Therefore, we aimed to evaluate women's attitude towards possible future human platelet antigen-screening in pregnancy. MATERIAL AND METHODS: We performed a cross-sectional questionnaire study among healthy pregnant women receiving prenatal care in one of seven participating midwifery practices. Attitude was assessed using a questionnaire based on the validated Multidimensional Measurement of Informed Choice model, containing questions assessing knowledge, attitude and intention to participate. RESULTS: A total of 143 of the 220 women (65%) completed and returned the questionnaire. A positive attitude towards human platelet antigen-screening was expressed by 91% of participants, of which 94% was based on sufficient knowledge. Attitude was more likely to be negatively influenced by the opinion that screening can be frightening. Informed choices were made in 87% and occurred significantly less in women from non-European origin, 89% in European women vs. 60% in non-European women (p = 0.03). CONCLUSIONS: Pregnant women in the Netherlands expressed a positive attitude towards human platelet antigen-screening in pregnancy. We therefore expect a high rate of informed uptake when human platelet antigen-screening is implemented. In future counseling on human platelet antigen-screening, ethnicity and possible anxiety associated with a screening test need to be specifically addressed.
[Mh] Termos MeSH primário: Testes Genéticos
Conhecimentos, Atitudes e Prática em Saúde
Diagnóstico Pré-Natal
Trombocitopenia Neonatal Aloimune/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Antígenos de Plaquetas Humanas/genética
Estudos Transversais
Feminino
Seres Humanos
Tocologia/estatística & dados numéricos
Países Baixos
Gravidez
Inquéritos e Questionários
Trombocitopenia Neonatal Aloimune/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antigens, Human Platelet)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1111/aogs.13150


  4 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28295360
[Au] Autor:Reiher VSA; Hönger G; Infanti L; Passweg JR; Hösli I; Frey BM; Gassner C; Meyer S; Buser AS; Holbro A; Schaub S
[Ad] Endereço:Regional Blood Transfusion Service, Swiss Red Cross.
[Ti] Título:Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization.
[So] Source:Transfusion;57(5):1272-1279, 2017 May.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Alloimmunization against human platelet antigens (HPAs) during pregnancy is rare but can lead to severe bleeding disorders, such as fetal and neonatal alloimmune thrombocytopenia. STUDY DESIGN AND METHODS: In a cohort of 241 uncomplicated pregnancies, we investigated the immunogenicity of HPA mismatches and correlated HLA sensitization with HPA antibody formation. HPA antibodies were measured with a Luminex-based multiplex assay. RESULTS: HPA mismatches were observed in 109 of 241 pregnancies (45%), but child-specific HPA antibodies were only found in two of 109 cases (2%), indicating a low immunogenicity. Only nine of 241 women (4%) had detectable HPA antibodies. HLA sensitization was identified as a strong and independent predictor for HPA antibody formation (hazard ratio, 10.2; 95% confidence interval, 1.8-193; p = 0.006), whereas the number of pregnancies was not. CONCLUSION: Our observational data indicated a low immunogenicity of HPA and suggest that a broader immune response-inferred by HLA sensitization-is probably associated with HPA antibody induction.
[Mh] Termos MeSH primário: Antígenos de Plaquetas Humanas/imunologia
Antígenos HLA/imunologia
[Mh] Termos MeSH secundário: Adulto
Formação de Anticorpos/imunologia
Estudos de Coortes
Feminino
Histocompatibilidade Materno-Fetal
Seres Humanos
Gravidez
Trombocitopenia Neonatal Aloimune/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antigens, Human Platelet); 0 (HLA Antigens)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14053


  5 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262226
[Au] Autor:Bonstein L; Haddad N
[Ad] Endereço:Blood Bank and Platelet Immunology Laboratory, Rambam Health Care Campus, Haifa, Israel. Electronic address: l_bonstein@rambam.health.gov.il.
[Ti] Título:Taking a wider view on fetal/neonatal alloimmune thrombocytopenia.
[So] Source:Thromb Res;151 Suppl 1:S100-S102, 2017 Mar.
[Is] ISSN:1879-2472
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In fetal/neonatal alloimmune thrombocytopenia (FNAIT), platelets are destroyed by maternal antibodies directed against fetal/neonate antigens. Thrombocytopenia can be severe and lead to intracranial hemorrhage (ICH) in about 10% of cases. Although three types of antigen groups, presented on platelets [ABO blood group antigens, human leukocyte antigens (HLA) and human platelet antigens (HPA)] are known to be implicated in immune platelet destruction, antibodies against HPA are most commonly involved in FNAIT and hence are the target of extensive research. Awareness of FNAIT by physicians as well as the availability of the most sensitive diagnostic methods capable of detecting a wide range of antibodies are crucial for the diagnosis of FNAIT and the prevention of severe thrombocytopenia and its bleeding risks in subsequent pregnancies.
[Mh] Termos MeSH primário: Antígenos de Plaquetas Humanas/imunologia
Plaquetas/patologia
Trombocitopenia Neonatal Aloimune/diagnóstico
Trombocitopenia Neonatal Aloimune/imunologia
[Mh] Termos MeSH secundário: Sistema do Grupo Sanguíneo ABO/análise
Sistema do Grupo Sanguíneo ABO/imunologia
Anticorpos/análise
Anticorpos/imunologia
Antígenos de Plaquetas Humanas/análise
Plaquetas/imunologia
Antígenos HLA/análise
Antígenos HLA/imunologia
Seres Humanos
Recém-Nascido
Trombocitopenia Neonatal Aloimune/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ABO Blood-Group System); 0 (Antibodies); 0 (Antigens, Human Platelet); 0 (HLA Antigens)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  6 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28236317
[Au] Autor:Hopkins M; Lucas G; Calvert A; Bendukidze N; Green F; Kotecha K; Poles A
[Ad] Endereço:H&I Department, IBGRL, NHSBT Filton, Bristol, UK.
[Ti] Título:Human platelet antigen (HPA)-specific immunoglobulin M antibodies in neonatal alloimmune thrombocytopenia can inhibit the binding of HPA-specific immunoglobulin G antibodies.
[So] Source:Transfusion;57(5):1267-1271, 2017 May.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A term baby with unexplained thrombocytopenia and a platelet (PLT) count of 14 × 10 /L (maternal PLT count was 200 × 10 /L) was investigated for neonatal alloimmune thrombocytopenia. STUDY DESIGN AND METHODS: Serologic investigations were performed using the PLT immunofluorescence test (PIFT), monoclonal antibody immobilization of PLT antigens (MAIPA), and a bead-based assay (BBA) with maternal sera taken up to 56 days postdelivery. One serum sample was also separated into "immunoglobulin (Ig)M-rich" and "IgM-depleted" fractions and tested for PLT-specific antibodies. The family was genotyped for HPA. RESULTS: HPA-3a-specific IgM antibodies were detected in the PIFT and confirmed in the BBA. PLT-specific IgG HPA-3a antibodies were not detected in the MAIPA assay and BBA in the initial sample but were detected in both techniques in subsequent serum samples. Testing of IgM-rich and IgM-depleted fractions in the MAIPA assay revealed that IgG antibody binding of the IgM-depleted fraction was inhibited by approximately 50% when it was reconstituted with the IgM-rich fraction suggesting that the IgM antibodies blocked the binding of the IgG antibodies. This effect was not observed when the IgM-depleted fraction or untreated serum was diluted with elution buffer. Incompatibility for HPA-3 was identified between the mother and the infant. The infant received one HPA-1a, -5b negative neonatal PLT transfusion, and one random PLT transfusion, with satisfactory outcomes. Both units were later found to be HPA-3b3b. CONCLUSION: HPA-3a IgM antibodies can inhibit PLT-specific HPA-3a IgG antibodies in the MAIPA assay.
[Mh] Termos MeSH primário: Antígenos de Plaquetas Humanas/imunologia
Imunoglobulina G/imunologia
Imunoglobulina M/imunologia
Isoanticorpos/imunologia
Trombocitopenia Neonatal Aloimune/imunologia
[Mh] Termos MeSH secundário: Sítios de Ligação de Anticorpos/imunologia
Seres Humanos
Testes Imunológicos
Recém-Nascido
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3a alloantigen, human); 0 (Antigens, Human Platelet); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (Isoantibodies)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170226
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14047


  7 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28130210
[Au] Autor:Winkelhorst D; Murphy MF; Greinacher A; Shehata N; Bakchoul T; Massey E; Baker J; Lieberman L; Tanael S; Hume H; Arnold DM; Baidya S; Bertrand G; Bussel J; Kjaer M; Kaplan C; Kjeldsen-Kragh J; Oepkes D; Ryan G
[Ad] Endereço:Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.
[Ti] Título:Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review.
[So] Source:Blood;129(11):1538-1547, 2017 Mar 16.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Several strategies can be used to manage fetal or neonatal alloimmune thrombocytopenia (FNAIT) in subsequent pregnancies. Serial fetal blood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as weekly maternal IV immunoglobulin infusion (IVIG), with or without additional corticosteroid therapy, are common options, but optimal management has not been determined. The aim of this systematic review was to assess antenatal treatment strategies for FNAIT. Four randomized controlled trials and 22 nonrandomized studies were included. Pooling of results was not possible due to considerable heterogeneity. Most studies found comparable outcomes regarding the occurrence of intracranial hemorrhage, regardless of the antenatal management strategy applied; FBS, IUPT, or IVIG with or without corticosteroids. There is no consistent evidence for the value of adding steroids to IVIG. FBS or IUPT resulted in a relatively high complication rate (consisting mainly of preterm emergency cesarean section) of 11% per treated pregnancy in all studies combined. Overall, noninvasive management in pregnant mothers who have had a previous neonate with FNAIT is effective without the relatively high rate of adverse outcomes seen with invasive strategies. This systematic review suggests that first-line antenatal management in FNAIT is weekly IVIG administration, with or without the addition of corticosteroids.
[Mh] Termos MeSH primário: Cuidado Pré-Natal/métodos
Trombocitopenia Neonatal Aloimune/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Gerenciamento Clínico
Feminino
Doenças Fetais/tratamento farmacológico
Seres Humanos
Imunoglobulinas Intravenosas/uso terapêutico
Recém-Nascido
Hemorragias Intracranianas/prevenção & controle
Mães
Gravidez
Esteroides/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous); 0 (Steroids)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2016-10-739656


  8 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28097780
[Au] Autor:Barg AA; Ifrah AD; Strauss T; Simchen MJ; Orvieto R; Rosenberg N; Kenet G
[Ad] Endereço:Thrombosis Institute and National Hemophilia Center, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
[Ti] Título:A man-made disease: Fetal neonatal alloimmune thrombocytopenia due to incompatibility between oocyte donor and gestational mother.
[So] Source:Pediatr Blood Cancer;64(8), 2017 Aug.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The incompatibility causing fetal and neonatal alloimmune thrombocytopenia (FNAIT) results from a fetus inheriting a paternal human platelet antigen (HPA), which is different from the maternal HPA. We present a unique case of FNAIT in a pregnancy involving an oocyte recipient mother with Turner syndrome. This is the first report of FNAIT in which the suggested mechanism involves antibodies produced by a gestational mother against the incompatible HPA of the oocyte donor.
[Mh] Termos MeSH primário: Antígenos de Plaquetas Humanas/genética
Trombocitopenia Neonatal Aloimune/genética
Doadores de Tecidos
[Mh] Termos MeSH secundário: Adulto
Feminino
Genótipo
Seres Humanos
Gravidez
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Human Platelet)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26447


  9 / 283 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28060120
[Au] Autor:Rotz SJ; Palumbo JS; Ware RE
[Ad] Endereço:Cancer and Blood Diseases Institute, Division of Hematology Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
[Ti] Título:Type 2B von Willebrand Disease: An Unusual Cause of Severe Neonatal Thrombocytopenia.
[So] Source:J Pediatr Hematol Oncol;39(6):473-475, 2017 Aug.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An infant with presumed maternal immune thrombocytopenic purpura had persistent thrombocytopenia with platelet clumping. The patient had no significant bleeding symptoms in the first year of life and von Willebrand antigen and ristocetin cofactor activity were normal. Absent high molecular weight multimers ultimately led to a genetically proven diagnosis of type 2B von Willebrand disease (3964G>A VWF exon 28), highlighting the challenges of establishing this diagnosis in infants.
[Mh] Termos MeSH primário: Trombocitopenia Neonatal Aloimune/etiologia
Doença de von Willebrand Tipo 2/complicações
Doença de von Willebrand Tipo 2/diagnóstico
[Mh] Termos MeSH secundário: Proteína ADAMTS13/genética
Anticorpos/sangue
Plaquetas/imunologia
Diagnóstico Diferencial
Seres Humanos
Lactente
Mães
Mutação
Doença de von Willebrand Tipo 2/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); EC 3.4.24.87 (ADAMTS13 Protein)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000000741


  10 / 283 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28019029
[Au] Autor:Wienzek-Lischka S; König IR; Papenkort EM; Hackstein H; Santoso S; Sachs UJ; Bein G
[Ad] Endereço:Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany.
[Ti] Título:HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia.
[So] Source:Transfusion;57(3):533-540, 2017 Mar.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Most cases of fetal and neonatal alloimmune thrombocytopenia (FNAIT) are caused by maternal alloantibodies against human platelet antigen-1a (HPA-1a). Alloimmunization mainly occurs in HPA-1a-negative mothers who are carriers of the HLA-DRB3*01:01 allele. Recently, it has been reported that the combined presence of HLA-DRB3*01:01 and HLA-DRB4*01:01P was associated with severity of FNAIT. We tested this hypothesis by analyzing a large cohort of cases and controls. STUDY DESIGN AND METHODS: In total, 101 mothers with a history of FNAIT caused by anti-HPA-1a were investigated. HLA-DRB1, -DRB3, -DRB4, and -DRB5 genotypes were determined by Luminex technology. Haplotype frequencies were compared between cases and 100 controls. The platelet (PLT) counts of neonates and the incidence of intracranial hemorrhage (ICH) were compared between subgroups defined by genotype. RESULTS: Of the HPA-1a-immunized mothers, 98% (99/101) carried at least one copy of HLA-DRB3*01:01. Carriage of HLA-DRB3*01:01 was significantly associated with immune response to HPA-1a (odds ratio, 92.3; 95% confidence interval, 26.9-317.1; p = 1.34 × 10 ). No association between HLA-DRB3*01:01 and HLA-DRB4*01:01P alone or in combination with the PLT count of the newborns or the incidence of ICH was detected. CONCLUSION: In contrast to HLA-DRB4*01:01P, the inheritance of HLA-DRB3*01:01 is strongly associated with the propensity for mounting a humoral immune response against fetal HPA-1a antigen. Neither a homozygous nor a compound heterozygous gene dose predicts the severity of the disease. Testing for the presence of HLA-DRB3*01:01 might be very useful in counseling women at risk of FNAIT due to anti-HPA-1a.
[Mh] Termos MeSH primário: Antígenos de Plaquetas Humanas
Doenças Fetais
Cadeias HLA-DRB3
Haplótipos
Imunidade Humoral
Trombocitopenia Neonatal Aloimune
[Mh] Termos MeSH secundário: Antígenos de Plaquetas Humanas/sangue
Antígenos de Plaquetas Humanas/genética
Antígenos de Plaquetas Humanas/imunologia
Feminino
Doenças Fetais/sangue
Doenças Fetais/genética
Doenças Fetais/imunologia
Cadeias HLA-DRB3/sangue
Cadeias HLA-DRB3/genética
Cadeias HLA-DRB3/imunologia
Seres Humanos
Recém-Nascido
Masculino
Valor Preditivo dos Testes
Trombocitopenia Neonatal Aloimune/sangue
Trombocitopenia Neonatal Aloimune/genética
Trombocitopenia Neonatal Aloimune/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1a alloantigen, human); 0 (Antigens, Human Platelet); 0 (HLA-DRB3 Chains)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE
[do] DOI:10.1111/trf.13950



página 1 de 29 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde